Efficacy and safety of sofosbuvir/velpatasvir alone or in combination with ribavirin in treatment of patients with genotype 3B HCV/HIV infection

Li LIU; Lixian CHANG; Zhiyong CHEN; Junyi LI; Chunyun LIU

doi:10.12449/JCH240209

Volume 40 Issue 2

Feb. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(2): 271-277

PDF( 800 KB)

Efficacy and safety of sofosbuvir/velpatasvir alone or in combination with ribavirin in treatment of patients with genotype 3B HCV/HIV infection

DOI: 10.12449/JCH240209

Li LIU¹,
Lixian CHANG¹,
Zhiyong CHEN²,
Junyi LI^{1
,
,
,},
Chunyun LIU^{1
,
,
,}

1.
Yunnan Provincial Clinical Medical Center for Infectious Diseases，The Third People’s Hospital of Kunming，Kunming 650041，China
2.
Department of Infectious Diseases，The First People’s Hospital of Zaoyang，Zaoyang，Hubei 430000，China

Research funding:

Scientific Research Special Fund of YouAn College Union (LM202014)

More Information

Corresponding author: LI Junyi， 759725784@qq.com （ORCID： 0000-0002-0813-3989）; LIU Chunyun， 751440760@qq.com （ORCID： 0000-0001-5343-5305）
Received Date: 2023-05-16
Accepted Date: 2023-07-27
Published Date: 2024-02-19

Abstract

Abstract

Objective To investigate the efficacy and safety of sofosbuvir/velpatasvir alone or in combination with ribavirin in Chinese patients with genotype 3B HCV/HIV infection. Methods A total of 299 patients with genotype 3B HCV/HIV infection who attended The Third People’s Hospital of Kunming from January 2017 to December 2020 were enrolled and treated with sofosbuvir/velpatasvir alone or in combination with ribavirin for 12 weeks， and they were followed up for 12 weeks after drug withdrawal. The patients were evaluated in terms of sustained virologic response at 12 weeks after treatment （SVR12） and adverse reactions. The independent-samples t test or the Mann-Whitney U test was used for comparison of continuous data between two groups， and the chi-square test was used for comparison of categorical data between two groups； the Agresti-Coull method was used to evaluate the 95% confidence interval （CI） of SVR12； univariate and multivariate non-conditional logistic regression analyses were used to investigate the influencing factors for SVR. Results The 299 patients with genotype 3B HCV/HIV infection had a mean age of 43.92±6.84 years， among whom the male patients accounted for 77.3% （231/299）， the patients with liver cirrhosis accounted for 36.5% （109/299）， the patients with a history of antiviral therapy accounted for 13.4% （40/299）， and the patients receiving sofosbuvir/velpatasvir combined with ribavirin accounted for 27.8% （83/299）. The overall SVR was 87.0% （260/299） for all patients， and there was no significant difference in SVR12 between the patients receiving sofosbuvir/velpatasvir alone and those receiving sofosbuvir/velpatasvir combined with ribavirin （87.5% vs 85.5%， χ²=0.203， P=0.653）. There was a significant difference in SVR12 between the patients without liver cirrhosis and those with liver cirrhosis （90.0% vs 81.7%， χ²=4.256， P=0.039）， and the patients receiving antiviral therapy for the first time had a significantly higher SVR12 than the treatment-experienced patients （93.4% vs 45.0%， χ²=71.670， P<0.001）. The univariate and multivariate logistic regression analyses showed that platelet count （odds ratio ［OR］=0.957， 95%CI： 0.931 — 0.984， P=0.002）， liver stiffness measurement （OR=1.446， 95%CI： 1.147 — 1.822， P=0.002）， and experience in treatment （OR=13.807， 95%CI： 2.970 — 64.174， P=0.001） were independent influencing factors for SVR in patients with genotype 3B HCV/HIV infection. There were 41 cases of serious adverse events， all of which occurred within 2 weeks after antiviral therapy， and 28 cases were resolved without drug withdrawal or active treatment， while 13 cases were not resolved after active treatment and were resolved after the antiviral drugs were stopped for 2‍ ‍—‍ ‍5 days， with no similar reactions observed when the drugs were used again after remission. Conclusion Sofosbuvir/velpatasvir alone or in combination with ribavirin has relatively good efficacy and safety in patients with genotype 3B HCV/HIV infection.
- Hepacivirus,
- HIV,
- Sofosbuvir,
- Velpatasvir,
- Ribavirin

FullText(HTML)

References(13)

References

[1]	World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection[M]. Geneva: World Health Organization, 2018.
[2]	World Health Organization. Global hepatitis report[R]. Geneva: WHO, 2017.
[3]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2019 version)[J]. J Clin Hepatol, 2019, 35( 12): 2670- 2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008. 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2670- 2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.
[4]	XU AQ, ZHANG L. The review and significance of national seroepidemiological surveys on viral hepatitis in China[J]. Chin J Prevent Med, 2017, 51( 6): 457- 461. DOI: 10.3760/cma.j.issn.0253-9624.2017.06.001. 徐爱强, 张丽. 中国病毒性肝炎血清流行病学调查的回顾与意义[J]. 中华预防医学杂志, 2017, 51( 6): 457- 461. DOI: 10.3760/cma.j.issn.0253-9624.2017.06.001.
[5]	YANG YQ, SHANG J, LU CZ, et al. Influencing factors for direct-acting antiviral therapy failure in treatment of hepatitis C[J]. J Clin Hepatol, 2022, 38( 5): 1059- 1063. DOI: 10.3969/j.issn.1001-5256.2022.05.016. 杨宇晴, 尚佳, 卢诚震, 等. 直接抗病毒药物治疗丙型肝炎失败的影响因素分析[J]. 临床肝胆病杂志, 2022, 38( 5): 1059- 1063. DOI: 10.3969/j.issn.1001-5256.2022.05.016.
[6]	HE QF, HU R, ZENG YL, et al. Efficacy and safety of Sofosbuvir/Velpatasvir with or without ribavirin in treatment of patients with chronic hepatitis C virus genotype 3 infection: A real-world study[J/CD]. Chin J Liver Dis(Electronic Version), 2022, 14( 1): 6- 13. DOI: 10.3969/j.issn.1674-7380.2022.01.002. 贺秋凤, 胡蓉, 曾义岚, 等. 索磷布韦/维帕他韦联合或不联合利巴韦林治疗基因3型慢性丙型肝炎病毒感染者的疗效及安全性: 一项真实世界研究[J/CD]. 中国肝脏病杂志(电子版), 2022, 14( 1): 6- 13. DOI: 10.3969/j.issn.1674-7380.2022.01.002.
[7]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006. 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
[8]	GAYAM V, HOSSAIN MR, KHALID M, et al. Real-world clinical efficacy and tolerability of direct-acting antivirals in hepatitis C monoinfection compared to hepatitis C/human immunodeficiency virus coinfection in a community care setting[J]. Gut Liver, 2018, 12( 6): 694- 703. DOI: 10.5009/gnl18004.
[9]	MACHADO SM, VIGANI AG, LEITE AG, et al. Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study[J]. Medicine, 2020, 99( 30): e21270. DOI: 10.1097/MD.0000000000021270.
[10]	TANG Q, WEI L, LIU XQ, et al. Sofosbuvir-based therapies achieved satisfactory virological response in Chinese individuals with genotypes 3 and 6 infections: A real-world experience[J]. Infect Drug Resist, 2021, 14: 2297- 2307. DOI: 10.2147/IDR.S312902.
[11]	ATSUKAWA M, TSUBOTA A, KONDO C, et al. Real-world clinical application of 12-week sofosbuvir/velpatasvir treatment for decompensated cirrhotic patients with genotype 1 and 2: A prospective, multicenter study[J]. Infect Dis Ther, 2020, 9( 4): 851- 866. DOI: 10.1007/s40121-020-00329-y.
[12]	MANGIA A, MILLIGAN S, KHALILI M, et al. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts[J]. Liver Int, 2020, 40( 8): 1841- 1852. DOI: 10.1111/liv.14537.
[13]	JI FP, LI J, LIU L, et al. High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b[J]. J Gastroenterol Hepatol, 2021, 36( 3): 767- 774. DOI: 10.1111/jgh.15192.

Relative Articles

[1]	Mengying ZHU, Ping YU, Guohong GE, Yuqi MA, Xiling FU, Jiabao CHANG. Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous direct-acting antiviral agent failure[J]. Journal of Clinical Hepatology, 2024, 40(11): 2201-2204. doi: 10.12449/JCH241112
[2]	Committee on HIV/Liver Diseases， Chinese Association of STD and AIDS Prevention and Control； Guangzhou Eighth People’s Hospital， Guangzhou Medical University. Chinese expert consensus on the diagnosis and treatment of HIV co-infection with HBV and HCV[J]. Journal of Clinical Hepatology, 2024, 40(6): 1107-1113. doi: 10.12449/JCH240607
[3]	Wei ZHANG, Song ZHAI, Hong DU, Fuchun JING, Limei WANG, Ye ZHANG, Bibo KANG, Jiuping WANG, Shuangsuo DANG, Jianqi LIAN, Hong JIANG. Efficacy and safety of the 12-week sofosbuvir-coblopasvir regimen in treatment of chronic hepatitis C[J]. Journal of Clinical Hepatology, 2023, 39(3): 539-545. doi: 10.3969/j.issn.1001-5256.2023.03.009
[4]	Jiajun LU, Fazhu FEI, Bin REN. Research advances in nonalcoholic fatty liver disease in individuals with HIV infection[J]. Journal of Clinical Hepatology, 2023, 39(6): 1446-1453. doi: 10.3969/j.issn.1001-5256.2023.06.030
[5]	Bianli DANG, Wenzhen KANG, Mingyuan BI, Jianhui LI, Zhaoyun CHEN, Shupeng LI, Qing LIU, Yongtao SUN, Weiping CAI, Wen KANG. Efficacy of switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combined with sofosbuvir/velpatasvir in treatment of previously untreated chronic hepatitis C patients with HIV/HCV co-infection and its influence on blood lipid levels[J]. Journal of Clinical Hepatology, 2022, 38(3): 541-546. doi: 10.3969/j.issn.1001-5256.2022.03.010
[6]	Haohui DENG, Shuifeng LI, Qianchang FENG, Linghua LI. Naturally occurring resistance-associated variants to NS3/4A protease and NS5A inhibitors in patients with HIV/HCV co-infection or HCV infection alone[J]. Journal of Clinical Hepatology, 2022, 38(2): 328-333. doi: 10.3969/j.issn.1001-5256.2022.02.015
[7]	Qiu Chen, Jia ShengNan, Zhang Qian, Zhang ChuanHui, Jin ZhenJing, Yang LanLan. Patients with mixed genotype hepatitis C virus infection treated by sofosbuvir/velpatasvir/ribavirin: A case report[J]. Journal of Clinical Hepatology, 2020, 36(7): 1591-1592. doi: 10.3969/j.issn.1001-5256.2020.07.028
[8]	Yang XiuMei, Halimulati Abdusalamu, Ji Dong, Wang ChunYan, Chen SongHai, Fu YiMing, Yang WuCai, Li ZhongBin. Efficiency of transient elastography in diagnosis of liver fibrosis in patients with HIV/HCV co-infection[J]. Journal of Clinical Hepatology, 2020, 36(8): 1732-1736. doi: 10.3969/j.issn.1001-5256.2020.08.011
[9]	Wang Mei, Xiong HuaGang, Yang ZhiGang, Long Hai, Wang Yi, Tan Li. HCV genotype and clinical features of patients with HIV/HCV coinfection in Guizhou,China: An analysis of 383 cases[J]. Journal of Clinical Hepatology, 2020, 36(10): 2203-2208. doi: 10.3969/j.issn.1001-5256.2020.10.009
[10]	Chen Xu, Su MingHua, Jiang JianNing, Liu ZhiHong, Wei Qi, Wu FeiFei, Zhou Yi, Teng ChunLing. Epidemiological features of positive anti-HCV among the HIV-infected population in Guangxi,China[J]. Journal of Clinical Hepatology, 2020, 36(1): 88-93. doi: 10.3969/j.issn.1001-5256.2020.01.020
[11]	He CaiNi, Li Yu, Ge Heng, Wei Fu, Ma XiaoTao, Wang WenJun, Gao Ning, Duan ChaoYang, Ji FanPu. Clinical effect and safety of sofosbuvir-based regimens in treatment of hepatitis C virus-associated glomerulonephritis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1714-1718. doi: 10.3969/j.issn.1001-5256.2019.08.013
[12]	Kou GuoXian, Wang Yu, Guo Jun, Liu Qian. Signal mining and analysis of the adverse drug reaction of digestive dysfunction caused by the new anti-HCV drug sofosbuvir[J]. Journal of Clinical Hepatology, 2018, 34(1): 68-72. doi: 10.3969/j.issn.1001-5256.2018.01.014
[13]	Chen ChiChi, Chen XiaoRong, Lu YunFei. A case of acute fulminant hepatitis B with HIV infection[J]. Journal of Clinical Hepatology, 2016, 32(9): 1787-1788. doi: 10.3969/j.issn.1001-5256.2016.09.033
[14]	Yin Fei, Zhou WeiHong. Clinical features of HIV/AIDS patients with digestive diseases[J]. Journal of Clinical Hepatology, 2016, 32(7): 1382-1387. doi: 10.3969/j.issn.1001-5256.2016.07.037
[15]	Wu ZhiFeng, Zhang GuangWen, Yang Xuan. Influence of concurrent HIV infection on antiviral therapy in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2015, 31(11): 1837-1840. doi: 10.3969/j.issn.1001-5256.2015.11.016
[16]	Liu JinHua, Zhao Yan, Sun HuanQin, Liu Ning, Qiao GuiFang, Wang ZiKang, Xu Jie, Li Ang, Zhang YongHong. Effect of HCV on disease progression in patients with HIV /HCV coinfection[J]. Journal of Clinical Hepatology, 2014, 30(6): 501-504. doi: 10.3969/j.issn.1001-5256.2014.06.006
[17]	Peng MiLin, Xiao XinQiang, Jiang YongFang, Tian Yi, Xu Yun, Zhang Min, Wang WenLong, Peng Feng, Gong GuoZhong. Preliminary study on effect of hepatitis C virus nonstructural protein 5A on HIV LTR[J]. Journal of Clinical Hepatology, 2014, 30(2): 136-140. doi: 10.3969/j.issn.1001-5256.2014.02.010
[18]	Sun HongQing, Huang Qin, Shen Fang, Wu Min, Zhou XiaoMing, Cai WeiPing, Hu YunWen. Effects of different anti- HIV therapies on progression of hepatitis C in HCV / HIV- coinfected patients[J]. Journal of Clinical Hepatology, 2013, 29(11): 835-838. doi: 10.3969/j.issn.1001-5256.2013.11.009
[19]	Wei Xin, Xie YuMei, Chen Lin, Pan Lei, Hao ChunQiu, Wang JiuPing, Bai XueFan, Jia ZhanSheng. Antiviral therapy with pegylated interferon alpha-2a plus ribavirin in patients with HCV related cirrhosis and to establish the grading for standard therapy[J]. Journal of Clinical Hepatology, 2011, 27(1): 89-92.
[20]	Kang WenZhen, Huang DeDong, Li Yuan, Zhuang Yan, Zhai Song, Zhao Ke, Xie YuMei, Sun YongTao. HIV-specific cytotoxic T-lymphocyte responses in patients co-infected with HIV and HCV[J]. Journal of Clinical Hepatology, 2011, 27(1): 68-71+80.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (589) PDF downloads(71)

Efficacy and safety of sofosbuvir/velpatasvir alone or in combination with ribavirin in treatment of patients with genotype 3B HCV/HIV infection

DOI: 10.12449/JCH240209

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Efficacy and safety of sofosbuvir/velpatasvir alone or in combination with ribavirin in treatment of patients with genotype 3B HCV/HIV infection

DOI: 10.12449/JCH240209

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content